Related Experiment Video
Updated: Oct 18, 2025
09:35
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
13.5K
Treatments for HBV: A Glimpse into the Future
Alessandra Bartoli1,2, Filippo Gabrielli1,3, Andrea Tassi1,3
1Department of Medical and Surgical Sciences, Division of Internal Medicine, Maternal-Infantile and Adult, University of Modena and Reggio Emilia, 41126 Modena, Italy.
Viruses
|September 28, 2021
Summary
New hepatitis B virus (HBV) treatments are being developed to target the virus's lifecycle, offering hope beyond current therapies that often require lifelong treatment for chronic liver disease and cancer.
Area of Science:
- Hepatology
- Virology
- Drug Discovery
Background:
- Hepatitis B virus (HBV) causes significant global chronic liver disease and liver cancer.
- Current therapeutic strategies have limited success in eradicating HBV and often necessitate lifelong treatment.
- There is a critical need for novel antiviral agents targeting distinct phases of the HBV lifecycle.
Purpose of the Study:
- To review and overview emerging therapeutic strategies for HBV infection.
- To highlight potential future treatments targeting the HBV lifecycle.
- To provide insights into advancements in antiviral drug development for hepatitis B.
Main Methods:
- Comprehensive literature review of recent studies on HBV therapeutics.
- Analysis of ongoing research into drugs targeting different stages of the HBV lifecycle.
- Synthesis of information on novel drug candidates and their mechanisms of action.
Main Results:
- Identification of multiple drug candidates targeting various HBV lifecycle phases.
- Evaluation of novel approaches, including host-targeting agents and direct-acting antivirals.
- Assessment of the potential for combination therapies to improve treatment outcomes.
Conclusions:
- Future HBV treatments are likely to involve drugs with novel mechanisms of action.
- Targeting the HBV lifecycle offers promising avenues for developing curative therapies.
- Continued research and development are essential to overcome the limitations of current HBV treatments.
More Related Videos
Related Concept Videos
01:10Retrovirus Life Cycles
47.7K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
47.7K
01:29Viruses with RNA Genomes
241
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
241
01:28Pulmonary Tuberculosis V
269
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
269
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
636
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
636
01:17Hepatic Drug Excretion: Enterohepatic Cycling
1.9K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
1.9K
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
28
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
28